Golden State Wealth Management LLC Takes $73,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Golden State Wealth Management LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, Holdings Channel.com reports. The firm bought 695 shares of the medical equipment provider’s stock, valued at approximately $73,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth about $28,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $35,000. R Squared Ltd purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth about $63,000. Finally, Mather Group LLC. increased its position in Zimmer Biomet by 100.9% during the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 332 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZBH. Raymond James decreased their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday. Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Friday. Barclays lowered their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday. Finally, Truist Financial reissued a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Down 0.5 %

NYSE:ZBH opened at $100.40 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $99.67 and a 52 week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market cap of $19.99 billion, a PE ratio of 22.56, a P/E/G ratio of 1.83 and a beta of 1.02. The business’s 50 day moving average is $107.34 and its two-hundred day moving average is $108.07.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the firm earned $2.20 earnings per share. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.96%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.